BioVentrix is a privately held medical device company on a mission to improve and expand the treatme
Location: United States, Connecticut, Mansfield
Employees: 11-50
Phone: +1 925-830-1000
Total raised: $60.5M
Founded date: 2003
Investors 1
| Date | Name | Website |
| 17.04.2023 | Andera Par... | anderapart... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.04.2023 | Series A | $48.5M | - |
| 09.07.2014 | - | $12M | - |
Mentions in press and media 17
| Date | Title | Description |
| 12.05.2026 | BioVentrix® Names Carl Byrnes Chief Financial Officer | BioVentrix, Inc. Carl Byrnes, CFO, BioVentrix, Inc. Adds Extensive Financial Leadership Experience to Senior Management Team “Carl brings deep financial management and investor relations expertise to BioVentrix. He will play a key role alon... |
| 26.03.2026 | BioVentrix, Inc. Announces German Reimbursement Designation | BioVentrix, Inc. 91 German Hospitals Now Eligible to Negotiate Full Coverage for Revivent Therapy Our team has successfully secured full reimbursement in Germany. Obtaining NUB Status 1a again for 2026 is an important component of our strat... |
| 03.11.2025 | First Patient Treated with BioVentrix® Revivent System in RELIVE Trial at Saint Luke’s Mid America Heart Institute | BioVentrix, Inc. Pivotal RELIVE Trial Is Evaluating the Safety and Efficacy of BioVentrix’s Revivent System in the Treatment of Patients Who Have Experienced Heart Failure For the right patient, treatment with the Revivent System could repr... |
| 16.09.2025 | BioVentrix Appoints Mark H. Ravich as Independent Board Member | BioVentrix, Inc. Seasoned Executive Brings Strategic Insight and Financial Expertise to Support Company’s Governance and Funding Initiatives I look forward to contributing to the work of the Board & supporting BioVentrix’s efforts to ad... |
| 10.09.2025 | BioVentrix Appoints William T. Abraham, MD and Rishi Puri, MD, PhD, FRACP to Board of Directors | BioVentrix, Inc. Renowned cardiovascular experts bring decades of clinical, research & leadership experience to support BioVentrix’s mission of advancing heart failure treatment We look forward to contributing as BioVentrix continues it... |
| 27.08.2025 | BioVentrix Names Vinod H. Thourani, MD and Marat Fudim, MD, MHS as National Co-Principal Investigators for RELIVE Trial | BioVentrix, Inc. Renowned Cardiologists to Lead Pivotal Trial Evaluating the BioVentrix Revivent System for Heart Failure Patients Dr. Thourani & Dr. Fudim bring world-class surgical and clinical research expertise to the RELIVE trial. ... |
| 21.01.2025 | BioVentrix® Names Steven Chartier President and Co-Chief Executive Officer | BioVentrix, Inc. Brings Extensive Leadership Experience to Senior Management Team Steve brings strong executive management & clinical operations experience to BioVentrix. He will be instrumental building a financially successful, patien... |
| 13.04.2023 | BioVentrix Raises $48.5M in Series A Funding | BioVentrix, a San Ramon, CA-based medical device company, raised $48.5M in Series A funding. The round was led by Andera Partners with participation from Cormorant Asset Management, Taglich Brothers, Squarepoint Capital and Richmond Brother... |
| 13.04.2023 | BioVentrix closes $48.5M Series A for heart failure treatment | BioVentrix announced today that it completed a $48.5 million Series A financing round to support its treatment for heart failure. Mansfield, Massachusetts-based BioVentrix develops minimally invasive therapies. They treat the dilated left v... |
| 09.07.2014 | BioVentrix raises $12M for heart attack treatment | MassDevice.com On Call | MASSDEVICE ON CALL — BioVentrix reported a $12.4 million funding round for its Revivent heart failure treatment. San Ramon, Calif.-based BioVentrix said in an equity filing that the equity round, involving 195 unnamed investors, began Jan. ... |
Show more